
This review explores the central nervous system pathways involved in incretin-based therapies, focusing on glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptor agonists. These treatments, pivotal for managing obesity and type 2 diabetes, significantly influence energy balance and glucose regulation via neural mechanisms. The review highlights recent advances in understanding the central metabolic regulation mediated by these receptors, providing insights into their therapeutic potential and mechanisms of action.
Like
Save
Share